Advanced NGS Partnership Paves Way for More Accessible Personalized Medicine in Cancer
|
By LabMedica International staff writers Posted on 24 May 2015 |
|
New next generation sequencing (NGS) test panels have been developed to provide more affordable advanced NGS testing that can help doctors choose the most effective cancer treatments based on tumor type and an individual’s genetic profile, an important step towards making personalized medicine broadly accessible. First launch is of a NGS colon cancer test panel.
Selah Genomics, an EKF Diagnostics (Cardiff, UK) subsidiary, has launched “PrecisionPath” in partnership with Greenville Health Systems (GHS; Greenville, SC, USA) a leading community-based cancer institute. Launch of the first panel, PrecisionPath Colon, follows a successful one year trial with GHS, and will be the first commercial NGS panel molecular test for invasive colon cancer priced under USD 1,000 with a target turnaround time of less than 7 days per reportable result.
PrecisionPath Colon can be used to identify the specific growth drivers for colon cancer in an individual based on their genetic make-up. The test is also used to identify the cancer’s specific susceptibility to available treatments based on tumor type. PrecisionPath will thereby help oncologists select the most effective available therapy throughout treatment.
PrecisionPath Colon focuses on key actionable biomarkers that provide maximum clinical utility at a more affordable cost. Oncologists can simply collect appropriate tumor samples and ship them to Selah for analysis. Selah will extract the tumor tissue DNA, then profile at GHS’s Institute for Translational Oncology Research (GHS ITOR; Greenville, SC, USA) using leading-edge Ion Torrent NGS.
A clear concise report, provided to the oncologist via Selah’s secure web portal, differentiates between genes with proven clinical utility and others under clinical trial investigation. As the body of evidence for clinical utility grows, reports will be updated accordingly, providing doctors with a means to routinely integrate genomic analysis into the everyday care of cancer patients.
Initially PrecisionPath Colon will be available across GHS’s oncology treatment centers. EKF will next expand the service throughout the US, targeting oncologists and pathologists treating patients with invasive colorectal cancer. EKF plans to offer PrecisionPath panels for additional indications, including lung cancer, breast cancer, and melanoma, beginning in late 2015.
"The launch of PrecisionPath Colon, at a price under USD 1,000 coupled with a 7 day turnaround time, demonstrates EKF’s commitment to providing affordable access to world-class diagnostic testing,” said Julian Baines, CEO, EKF. Jeffrey Edenfield, MD, medical director of GHS ITOR, added, “We are excited by the opportunity to actively work with Selah to help standardize the availability of molecular medicine. Not everyone has a major academic cancer institute in their back yard, but everyone deserves access to a precise diagnosis and targeted treatment options.”
EKF and GHS’ partnership strengthens an already successful relationship, which began in March 2012 with the formation of Selah’s Clinical Genomics Centre at GHS. PrecisionPath has been developed in close association with leading cancer specialists from the initial piloting program at GHS ITOR in May 2013 until its commercial launch in May 2015. This partnership exists alongside the 18 month collaboration announced on 2 March 2015, partly funded by Becton Dickinson and Company and brings together Selah’s NGS technology and DecisionQ artificial intelligence-based decision support algorithms.
Related Links:
EKF Diagnostics
Selah Genomics
Greenville Health Systems – Institute for Translational Oncology Research
Selah Genomics, an EKF Diagnostics (Cardiff, UK) subsidiary, has launched “PrecisionPath” in partnership with Greenville Health Systems (GHS; Greenville, SC, USA) a leading community-based cancer institute. Launch of the first panel, PrecisionPath Colon, follows a successful one year trial with GHS, and will be the first commercial NGS panel molecular test for invasive colon cancer priced under USD 1,000 with a target turnaround time of less than 7 days per reportable result.
PrecisionPath Colon can be used to identify the specific growth drivers for colon cancer in an individual based on their genetic make-up. The test is also used to identify the cancer’s specific susceptibility to available treatments based on tumor type. PrecisionPath will thereby help oncologists select the most effective available therapy throughout treatment.
PrecisionPath Colon focuses on key actionable biomarkers that provide maximum clinical utility at a more affordable cost. Oncologists can simply collect appropriate tumor samples and ship them to Selah for analysis. Selah will extract the tumor tissue DNA, then profile at GHS’s Institute for Translational Oncology Research (GHS ITOR; Greenville, SC, USA) using leading-edge Ion Torrent NGS.
A clear concise report, provided to the oncologist via Selah’s secure web portal, differentiates between genes with proven clinical utility and others under clinical trial investigation. As the body of evidence for clinical utility grows, reports will be updated accordingly, providing doctors with a means to routinely integrate genomic analysis into the everyday care of cancer patients.
Initially PrecisionPath Colon will be available across GHS’s oncology treatment centers. EKF will next expand the service throughout the US, targeting oncologists and pathologists treating patients with invasive colorectal cancer. EKF plans to offer PrecisionPath panels for additional indications, including lung cancer, breast cancer, and melanoma, beginning in late 2015.
"The launch of PrecisionPath Colon, at a price under USD 1,000 coupled with a 7 day turnaround time, demonstrates EKF’s commitment to providing affordable access to world-class diagnostic testing,” said Julian Baines, CEO, EKF. Jeffrey Edenfield, MD, medical director of GHS ITOR, added, “We are excited by the opportunity to actively work with Selah to help standardize the availability of molecular medicine. Not everyone has a major academic cancer institute in their back yard, but everyone deserves access to a precise diagnosis and targeted treatment options.”
EKF and GHS’ partnership strengthens an already successful relationship, which began in March 2012 with the formation of Selah’s Clinical Genomics Centre at GHS. PrecisionPath has been developed in close association with leading cancer specialists from the initial piloting program at GHS ITOR in May 2013 until its commercial launch in May 2015. This partnership exists alongside the 18 month collaboration announced on 2 March 2015, partly funded by Becton Dickinson and Company and brings together Selah’s NGS technology and DecisionQ artificial intelligence-based decision support algorithms.
Related Links:
EKF Diagnostics
Selah Genomics
Greenville Health Systems – Institute for Translational Oncology Research
Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS
Latest Molecular Diagnostics News
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
Channels
Clinical Chemistry
view channel
3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more.jpg "Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)")
POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more
Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
The conventional methods for measuring free cortisol, the body's stress hormone, from blood or saliva are quite demanding and require sample processing. The most common method, therefore, involves collecting... Read more
Hematology
view channel
Next Generation Instrument Screens for Hemoglobin Disorders in Newborns
Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more
First 4-in-1 Nucleic Acid Test for Arbovirus Screening to Reduce Risk of Transfusion-Transmitted Infections
Arboviruses represent an emerging global health threat, exacerbated by climate change and increased international travel that is facilitating their spread across new regions. Chikungunya, dengue, West... Read more
POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy
Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more
First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy
Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read moreImmunology
view channel.jpg "Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)")
AI Predicts Tumor-Killing Cells with High Accuracy
Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more
Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more
AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
Current strategies for matching cancer patients with specific treatments often depend on bulk sequencing of tumor DNA and RNA, which provides an average profile from all cells within a tumor sample.... Read more
Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read moreMicrobiology
view channel
Integrated Solution Ushers New Era of Automated Tuberculosis Testing
Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more
Automated Sepsis Test System Enables Rapid Diagnosis for Patients with Severe Bloodstream Infections
Sepsis affects up to 50 million people globally each year, with bacteraemia, formerly known as blood poisoning, being a major cause. In the United States alone, approximately two million individuals are... Read more
Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases
GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more
Clinical Decision Support Software a Game-Changer in Antimicrobial Resistance Battle
Antimicrobial resistance (AMR) is a serious global public health concern that claims millions of lives every year. It primarily results from the inappropriate and excessive use of antibiotics, which reduces... Read morePathology
view channel
AI Integrated With Optical Imaging Technology Enables Rapid Intraoperative Diagnosis
Rapid and accurate intraoperative diagnosis is essential for tumor surgery as it guides surgical decisions with precision. Traditional intraoperative assessments, such as frozen sections based on H&E... Read more
HPV Self-Collection Solution Improves Access to Cervical Cancer Testing
Annually, over 604,000 women across the world are diagnosed with cervical cancer, and about 342,000 die from this disease, which is preventable and primarily caused by the Human Papillomavirus (HPV).... Read more
Hyperspectral Dark-Field Microscopy Enables Rapid and Accurate Identification of Cancerous Tissues
Breast cancer remains a major cause of cancer-related mortality among women. Breast-conserving surgery (BCS), also known as lumpectomy, is the removal of the cancerous lump and a small margin of surrounding tissue.... Read more
Technology
view channel
New Diagnostic System Achieves PCR Testing Accuracy
While PCR tests are the gold standard of accuracy for virology testing, they come with limitations such as complexity, the need for skilled lab operators, and longer result times. They also require complex... Read more
DNA Biosensor Enables Early Diagnosis of Cervical Cancer
Molybdenum disulfide (MoS2), recognized for its potential to form two-dimensional nanosheets like graphene, is a material that's increasingly catching the eye of the scientific community.... Read more
Self-Heating Microfluidic Devices Can Detect Diseases in Tiny Blood or Fluid Samples
Microfluidics, which are miniature devices that control the flow of liquids and facilitate chemical reactions, play a key role in disease detection from small samples of blood or other fluids.... Read more
Breakthrough in Diagnostic Technology Could Make On-The-Spot Testing Widely Accessible
Home testing gained significant importance during the COVID-19 pandemic, yet the availability of rapid tests is limited, and most of them can only drive one liquid across the strip, leading to continued... Read moreIndustry
view channel
Danaher and Johns Hopkins University Collaborate to Improve Neurological Diagnosis
Unlike severe traumatic brain injury (TBI), mild TBI often does not show clear correlations with abnormalities detected through head computed tomography (CT) scans. Consequently, there is a pressing need... Read more
Beckman Coulter and MeMed Expand Host Immune Response Diagnostics Partnership
Beckman Coulter Diagnostics (Brea, CA, USA) and MeMed BV (Haifa, Israel) have expanded their host immune response diagnostics partnership. Beckman Coulter is now an authorized distributor of the MeMed... Read more_1.jpg "Image: Thermo Fisher will distribute Bio-Techne products across Europe (Photo courtesy of 123RF)")
